Compare ABRDN Physical Gold Shares ETF (SGOL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ABRDN Physical Gold Shares ETF vs Tango Therapeutics Inc. — how do they compare? ABRDN Physical Gold Shares ETF trades at $39.52 (market cap $7.18B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: ABRDN Physical Gold Shares ETF is the larger of the two by market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ABRDN Physical Gold Shares ETF for 57 Days and Tango Therapeutics Inc. for 0 Days on average.
| SGOL | TNGX | |
|---|---|---|
Market Cap | $7.18B | $3.75B |
Volume | 2,482,796 | 9,619,106 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $51.41 | $32.90 |
52-Week Low | $37.54 | $7.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOL trades at $39.63, down 0.13% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX showing sell signals. Support levels cluster around $39-40, while resistance is firm at $40. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices pressured by rising rates but supported by geopolitical tensions and strong Chinese imports.
The outlook remains cautious amid interest rate uncertainty, with potential for rebound if yields stabilize or conflict escalates. Risks include persistent inflation driving higher rates, while institutional analysts see mixed paths—some targeting $4,100 by year-end but others $5,000 by mid-2027. Investor sentiment is neutral to bearish short-term.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
